Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Share News (HLN)

Share Price Information for Haleon (HLN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 322.60
Bid: 323.00
Ask: 323.10
Change: -4.30 (-1.32%)
Spread: 0.10 (0.031%)
Open: 328.50
High: 330.70
Low: 322.20
Prev. Close: 326.90
HLN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Retailers suffer as UK earnings lag inflation

Tue, 19th Jul 2022 08:39

(Alliance News) - Furniture seller Made.com on Tuesday lowered guidance as UK consumers rein in spending and warned that it may need to raise additional financing.

The warning from the retailer came as official figures showed UK earnings rising at only half the rate of inflation.

Made.com said gross sales in the first half of 2022 were down 19% year-on-year, though up 55% from pre-virus levels.

"Recent trading has been volatile, and the worsening of consumer confidence has impacted demand for discretionary big-ticket items, making new customer acquisition at financially attractive rates challenging," Made.com cautioned.

Profit for 2022 will take a GBP20 million one-off hit from clearance work related to excess inventory and additional costs in its supply chain.

For 2022, Made now expects gross sales to fall by between 15% to 30%. It had previously expected an outcome ranging from flat sales to a 15% fall.

Revenue guidance has been lowered to a range of a 9% fall to a 24% fall from between 8% growth and a 7% decline previously.

Made said it is considering options to strength its balance sheet, as it lowered its 2022 year-end cash forecast to between GBP5 million and GBP30 million from between GBP40 million and GBP65 million previously.

Made.com shares were down 37% early Tuesday at 24.15p.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: down 0.6% at 7,183.32

----------

Hang Seng: down 0.8% at 20,680.43

Nikkei 225: closed up 0.7% at 26,961.68

S&P/ASX 200: closed down 0.6% at 6,649.60

----------

DJIA: closed down 215.65 points, or 0.7%, at 31,072.61

S&P 500: closed down 32.31 points, or 0.8%, at 3,830.85

Nasdaq Composite: closed down 92.37 points, or 0.8%, at 11,360.05

----------

EUR: flat at USD1.0164 (USD1.0167)

GBP: soft at USD1.1970 (USD1.1994)

USD: lower at JPY137.74 (JPY138.17)

GOLD: lower at USD1,708.91 per ounce (USD1,709.33)

OIL (Brent): higher at USD106.29 a barrel (USD105.55)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Tuesday's key economic events still to come

1000 CEST EU ECB bank lending survey

1100 CEST EU harmonised consumer price index

1100 CEST EU construction output

0830 EDT US new residential construction

1630 EDT US API weekly statistical bulletin

0855 EDT US Johnson Redbook retail sales index

----------

The UK unemployment rate remained unchanged in the three months to May, in line with market expectations. The jobless rate was 3.8%, the same level as in the three months in April, according to the Office for National Statistics. A year earlier, the unemployment rate had sat at 4.9%. The latest figure was in line with FXStreet cited consensus.

----------

UK wage growth figures, meanwhile, showed average earnings including bonuses rose 6.2% on an annual basis, slowing from 6.8% in the reading for April and below FXStreet-cited consensus of 6.9%. Excluding bonuses, wages grew 4.3%, in line with consensus and picking up from 4.2% growth in April. That means UK earnings by both measures continue to lag consumer price inflation, which ran at 9.1% in May.

----------

BROKER RATING CHANGES

----------

Barclays starts Haleon with 'equal weight' - price target 348 pence

----------

Oddo BHF starts Vodafone with 'neutral' - price target 140 pence

----------

JPMorgan places Segro on 'positive catalyst watch'

----------

COMPANIES - FTSE 100

----------

Business publisher and events organiser Informa backed annual expectations. Informa still expects revenue between GBP2.15 billion to GBP2.25 billion for 2022, with adjusted operating profit between GBP470 million to GBP490 million. At best, this would represent revenue growth of 25% from GBP1.80 billion in 2021 and adjusted operating profit growth of 26% from GBP388.4 million. Guidance does not include any contribution from Industry Dive, which Informa announced it has acquired for up to USD525 million. The initial cash consideration is USD389 million. "Industry Dive brings a scalable, single proprietary technology platform, which will enable us to expand our digital services capabilities and deliver content led services to our B2B audiences," Informa said. Informa said that for the first half of 2022, it expects to report underlying revenue growth of 40%, helped by a return of live events.

----------

COMPANIES - FTSE 250

----------

Cybersecurity company Darktrace said it expects revenue growth of 48% in the financial fourth quarter that ended June 30. It forecasts an annualised recurring revenue climb of 42%. "Darktrace continued to deliver strong sales performance in its fourth quarter, adding over 500 net new customers, and bringing the group's customer base at year-end to over 7,400. This reflects year-over-year growth of approximately 32%," the company said. For the year, Darktrace expects revenue of USD417.0 million, up 48%. Its adjusted earnings before interest, tax, depreciation and amortisation margin is tipped to land at 19.5%, above its previous guidance range of 15% to 17%. For the new financial year, revenue growth will slow. Darktrace expects a revenue rise of between 29% and 32%. Growth has been hit by foreign currency movements. "It cautions that particularly for the first six-to-nine months of the year, year-over-year growth comparisons are expected to be dampened by the impact that significant movements in exchange rates relative to the prior year period have already had, and are expected to continue to have, on the conversion of British pound and euro-denominated ARR to US dollar-denominated revenue," Darktrace explained.

----------

COMPANIES - SMALL CAP

----------

Wise has kicked off its new financial year with growth in revenue and volumes. In the three months ended June, the international money transfer service provider said revenue grew 51% yearly to GBP185.9 million from GBP123.5 million. Quarter-on-quarter, revenue was up 21%. Transaction volumes were 49% higher yearly and 14% higher quarterly at GBP24.4 billion. "Volume growth was driven by a higher number of active customers that are increasingly using the Wise Account and Wise Business products, which in turn also leads to a higher average volume per customer. The growth also reflects to a lesser extent, more variable drivers which include people and businesses responding to increased levels of FX volatility and the translation impact from FX movements which was a tailwind in the quarter, compared with a headwind in FY22. On a constant currency basis volume grew 45% year-on-year," Wise explained. Wise left revenue guidance unchanged. It still expects annual growth of between 30% and 35% for financial 2023.

----------

COMPANIES - GLOBAL

----------

Novartis reported a drop in second-quarter income and a fall in sales but nonetheless reconfirmed its guidance for 2022 as a whole. The Basel, Switzerland-based pharmaceutical company posted net income of USD1.70 billion in the second quarter of 2022, representing a 36% drop against the previous year's figure of USD2.65 billion. Earnings per share fell by a similar percentage, dropping 36% to USD0.77 per share from USD1.19 the previous year. Net sales declined more modestly, slipping 1.4% to USD12.78 billion from USD12.96 billion. The firm explained that price erosion and competition from generic drugs was the reason behind the drop in sales. In contrast, key sales drivers were arthritis and psoriasis drug Cosentyx, heart failure treatment Entresto, spinal muscular atrophy drug Zolgensma, breast cancer drug Kisqali, multiple sclerosis therapy Kesimpta, and cholesterol drug Leqvio - all of which grew in double digits, Novartis added.

----------

Tuesday's shareholder meetings

Biotech Growth Trust PLC - AGM

Clean Power Hydrogen PLC - AGM

e-Therapeutics PLC - AGM

Norcros PLC - AGM

Ten Lifestyle Group PLC - GE re commitment to sustainability, B Corp certification

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
26 Jun 2024 17:04

LONDON MARKET CLOSE: CAC 40 underperforms amid political uncertainty

(Alliance News) - Stock prices in London closed lower on Wednesday, with eyes on two days of key US economic data to close of the week.

Read more
26 Jun 2024 15:32

London close: Stocks finish choppy day in the red

(Sharecast News) - London stocks ended in negative territory on Wednesday, influenced by a downturn in retail sales data for June.

Read more
26 Jun 2024 13:04

TOP NEWS: Haleon sells NRT business outside of US for GBP500 million

(Alliance News) - Haleon PLC on Wednesday said it has agreed to sell its nicotine replacement therapy business outside of the US to Dr Reddy's Laboratories SA.

Read more
26 Jun 2024 12:49

Haleon to sell NRT business outside of the US to Dr Reddy's for £500m

(Sharecast News) - Haleon said on Wednesday that it has agreed to sell its nicotine replacement therapy (NRT) business outside of the US to Dr Reddy's Laboratories for £500m.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 08:49

Berenberg starts coverage of Haleon at 'buy'

(Sharecast News) - Berenberg initiated coverage of consumer health company Haleon on Wednesday with a 'buy' rating and 407p price target.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
17 May 2024 17:38

London's FTSE nudges lower for week after record run

Haleon falls after GSK offloads remaining stake

*

Read more
17 May 2024 15:52

London close: Stocks recoup some earlier losses

(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.

Read more
17 May 2024 11:52

LONDON MARKET MIDDAY: FTSE 100 slides; Eurozone inflation steady

(Alliance News) - Stock prices in London were lacklustre at midday on Friday, as investors eye the trajectory of interest rates across the globe.

Read more
17 May 2024 09:03

TOP NEWS: GSK sells remaining Haleon stake for GBP1.25 billion

(Alliance News) - GSK PLC on Friday said it has sold its remaining shares in Haleon PLC, marking a total exit from its consumer healthcare spin-off.

Read more
17 May 2024 08:56

LONDON MARKET OPEN: FTSE 100 lacklustre as Wall Street rally ends

(Alliance News) - Stock prices in London opened lower on Friday, after Thursday saw Wall Street's rally end in a record breaking session.

Read more
17 May 2024 08:39

GSK raises $1.5 bln from sale of remaining Haleon stake

May 17 (Reuters) - British drugmaker GSK has raised 1.25 billion pounds ($1.52 billion) from a sale of its remaining stake in consumer healthcare company Haleon to institutional investors.

Read more
17 May 2024 07:42

LONDON BRIEFING: Land Securities ups dividend; GSK sells Haleon stake

(Alliance News) - Stocks in London are called to open lower, as investors wait for an inflation reading from the eurozone later this morning.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.